Trial Profile
A global, double-blind, placebo-controlled phase III study of oral pacritinib in patients with myelofibrosis
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 05 Mar 2013
Price :
$35
*
At a glance
- Drugs Pacritinib (Primary)
- Indications Myelofibrosis
- Focus Registrational; Therapeutic Use
- 05 Mar 2013 Status changed from planning to discontinued.
- 14 Dec 2011 New trial record